+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Skin Cancer Drugs Market Research Reports

From
Non-Melanoma Skin Cancer - Global Strategic Business Report - Product Thumbnail Image

Non-Melanoma Skin Cancer - Global Strategic Business Report

  • Report
  • April 2024
  • 196 Pages
  • Global
From
From
Melanoma Therapeutics: Global Strategic Business Report - Product Thumbnail Image

Melanoma Therapeutics: Global Strategic Business Report

  • Report
  • April 2024
  • 162 Pages
  • Global
From
Bulk Paclitaxel - Global Strategic Business Report - Product Thumbnail Image

Bulk Paclitaxel - Global Strategic Business Report

  • Report
  • April 2024
  • 184 Pages
  • Global
From
From
Kaposi Sarcoma - Global Strategic Business Report - Product Thumbnail Image

Kaposi Sarcoma - Global Strategic Business Report

  • Report
  • April 2024
  • 309 Pages
  • Global
From
Skin Cancer Diagnostics Global Market Report 2024 - Product Thumbnail Image

Skin Cancer Diagnostics Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Uveal Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Uveal Melanoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 90 Pages
  • Global
From
Gorlin-syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Gorlin-syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Unresectable Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Unresectable Melanoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Head and Neck Squamous Cell Carcinoma (HNSCC) - Pipeline Insight, 2024 - Product Thumbnail Image

Head and Neck Squamous Cell Carcinoma (HNSCC) - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Metastatic Cutaneous Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Cutaneous Melanoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Nonmelanoma Skin Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Nonmelanoma Skin Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Nevoid basal cell carcinoma syndrome (NBCCS) - Pipeline Insight, 2024 - Product Thumbnail Image

Nevoid basal cell carcinoma syndrome (NBCCS) - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Untreated Metastatic or Unresectable Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Untreated Metastatic or Unresectable Melanoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Metastatic Cutaneous Squamous Cell Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Cutaneous Squamous Cell Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
BRAF-Mutant Metastatic Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

BRAF-Mutant Metastatic Melanoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Loading Indicator

The Skin Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat skin cancer. These drugs are used to treat a variety of skin cancer types, including melanoma, basal cell carcinoma, and squamous cell carcinoma. The drugs are typically administered orally, intravenously, or topically. The market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Novartis, Pfizer, and Roche. These companies are constantly researching and developing new treatments to improve the efficacy of existing treatments and to develop new treatments for skin cancer. In addition to the major players, there are also many smaller companies that are developing treatments for skin cancer. These companies are often focused on developing treatments for rarer forms of skin cancer, such as Merkel cell carcinoma. Examples of these companies include Aduro Biotech, Arcutis Biotherapeutics, and OncoSec Medical. Show Less Read more